# Myla Lai-Goldman

> Myla Lai-Goldman is co-founder and chair of GeneCentric Therapeutics, which she led as CEO and president from 2011 through 2018. She previously spent more than eighteen years at Labcorp and its predecessor, with executive and operational responsibilities. She is also a venture partner at Hatteras Venture Partners, founder and managing partner of Personalized Science, and a director whose appointments include West Pharmaceutical Services and Quanterix.

- **Role:** Co-Founder and Chair at GeneCentric Therapeutics
- **Organizations:** GeneCentric Therapeutics, Hatteras Venture Partners, Personalized Science, LLC, West Pharmaceutical Services, Quanterix, NovoPath, Mercy BioAnalytics, Hitachi High-Tech America, Labcorp (former), Roche Biomedical Laboratories (former), CancerGuide Diagnostics (former), Akoya Biosciences (former), Qvella Corporation (former), Sequenom (former)
- **Education:** Bachelor’s degree in biology; concentration in ecology, University of Pennsylvania, Doctor of Medicine, Columbia University College of Physicians and Surgeons
- **Known for:** Co-founded GeneCentric and led it as CEO and president from its founding in 2011 through 2018., Held strategic and operating responsibilities for three major Labcorp laboratories comprising more than 700 people., Built a career spanning large-company operations, startup leadership, venture investing and public-company governance.

## Career timeline

- **1990** — Joined Roche Biomedical Laboratories, a predecessor of Labcorp.
- **1997** — Named a senior vice president at Labcorp.
- **1998** — Became executive vice president and chief scientific officer at Labcorp.
- **2008** — Founded Personalized Science, LLC. Retired from her Labcorp executive role effective December 31, with a consulting transition running January-April 2009.
- **2009-2010** — Served as CEO and chief scientific officer of CancerGuide Diagnostics from June 2009 to December 2010.
- **2011** — Co-founded GeneCentric with UNC researchers Charles Perou and Neil Hayes; became CEO and president. Joined Hatteras Venture Partners as venture partner in August.
- **2012** — Joined Sequenom’s board in September.
- **2014** — Appointed to West Pharmaceutical Services’ board on February 20.
- **2019** — On January 3, GeneCentric announced Michael Milburn as CEO and president and Lai-Goldman’s move to executive chair, succeeding Clay Thorp as board chair.
- **2021** — Joined Akoya Biosciences’ board in September.
- **2022** — Began service as a NovoPath director.
- **2023** — Began service as a Mercy BioAnalytics director.
- **2024** — Hitachi High-Tech America announced her appointment to its newly formed scientific advisory board on February 22.
- **2025** — Joined Quanterix’s board on July 8 following its acquisition of Akoya.

## Achievements

- Co-founded GeneCentric and led it as CEO and president from its founding in 2011 through 2018.
- Held strategic and operating responsibilities for three major Labcorp laboratories comprising more than 700 people.
- Built a career spanning large-company operations, startup leadership, venture investing and public-company governance.
- Appointed to West Pharmaceutical Services’ board in 2014.
- Appointed to Quanterix’s board in July 2025.

## Latest updates

- **2026-04** — Quanterix’s April 24 proxy statement identifies her as a director, with service beginning in July 2025.
- **2025-07** — Joined Quanterix’s board on July 8 when Quanterix completed its Akoya acquisition.
- **2024-02** — Named to Hitachi High-Tech America’s newly formed scientific advisory board.

## Links

- Website: https://genecentric.com/
- LinkedIn: https://www.linkedin.com/in/myla-lai-goldman-362b4314

---

Profile page: https://yespress.io/myla-lai-goldman
Published by YesPress — https://yespress.io
Last updated: 2026-10-21